Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Epigenomic Networking in Drug Development: From Pathogenic Mechanisms to Pharmacogenomics
Ramón Cacabelos
Drug Development Research (2014) Vol. 75, Iss. 6, pp. 348-365
Closed Access | Times Cited: 59

Showing 1-25 of 59 citing articles:

Epigenetics of Aging and Alzheimer’s Disease: Implications for Pharmacogenomics and Drug Response
Ramón Cacabelos, Clara Torrellas
International Journal of Molecular Sciences (2015) Vol. 16, Iss. 12, pp. 30483-30543
Open Access | Times Cited: 130
Anti-aging pharmacology: Promises and pitfalls
Alexander Vaiserman, Oleh Lushchak, Alexander Koliada
Ageing Research Reviews (2016) Vol. 31, pp. 9-35
Closed Access | Times Cited: 129
TALE-mediated epigenetic suppression of CDKN2A increases replication in human fibroblasts
Diana L. Bernstein, John E. Le Lay, Elena G. Ruano, et al.
Journal of Clinical Investigation (2015) Vol. 125, Iss. 5, pp. 1998-2006
Open Access | Times Cited: 123
The role of pharmacogenomics in adverse drug reactions
Ramón Cacabelos, Natalia Cacabelos, Juan C. Carril
Expert Review of Clinical Pharmacology (2019) Vol. 12, Iss. 5, pp. 407-442
Closed Access | Times Cited: 98
HDAC inhibitors: A new promising drug class in anti-aging research
E. G. Pasyukova, Alexander Vaiserman
Mechanisms of Ageing and Development (2017) Vol. 166, pp. 6-15
Closed Access | Times Cited: 90
Antiaging Strategies and Remedies: A Landscape of Research Progress and Promise
Rumiana Tenchov, Janet M. Sasso, Xinmei Wang, et al.
ACS Chemical Neuroscience (2024) Vol. 15, Iss. 3, pp. 408-446
Open Access | Times Cited: 12
The impact of genetic variability on Alzheimer’s therapies: obstacles for pharmacogenetic progress
Ramón Cacabelos, Olaia Martínez-Iglesias, Natalia Cacabelos, et al.
Expert Opinion on Drug Metabolism & Toxicology (2025), pp. 1-28
Closed Access | Times Cited: 1
Epigenetic drug discovery for Alzheimer’s disease
Ramón Cacabelos, Clara Torrellas
Expert Opinion on Drug Discovery (2014) Vol. 9, Iss. 9, pp. 1059-1086
Closed Access | Times Cited: 78
Sirtuins in Alzheimer’s Disease: SIRT2-Related GenoPhenotypes and Implications for PharmacoEpiGenetics
Ramón Cacabelos, Juan C. Carril, Natalia Cacabelos, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 5, pp. 1249-1249
Open Access | Times Cited: 76
AdoMet analog synthesis and utilization: current state of the art
Tyler D. Huber, Brooke Johnson, Jianjun Zhang, et al.
Current Opinion in Biotechnology (2016) Vol. 42, pp. 189-197
Open Access | Times Cited: 75
Have there been improvements in Alzheimer’s disease drug discovery over the past 5 years?
Ramón Cacabelos
Expert Opinion on Drug Discovery (2018) Vol. 13, Iss. 6, pp. 523-538
Closed Access | Times Cited: 62
Pharmacoepigenomic Interventions as Novel Potential Treatments for Alzheimer’s and Parkinson’s Diseases
Óscar Teijido, Ramón Cacabelos
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 10, pp. 3199-3199
Open Access | Times Cited: 57
Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia
Ramón Cacabelos
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 9, pp. 3059-3059
Open Access | Times Cited: 48
Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer’s disease
Ramón Cacabelos
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 8, pp. 673-701
Closed Access | Times Cited: 42
Metabolic disorder in Alzheimer’s disease
Mrinal K. Poddar, Soumyabrata Banerjee, Apala Chakraborty, et al.
Metabolic Brain Disease (2021) Vol. 36, Iss. 5, pp. 781-813
Closed Access | Times Cited: 38
Natural Bioactive Products as Epigenetic Modulators for Treating Neurodegenerative Disorders
Olaia Martínez-Iglesias, Vinogran Naidoo, Iván Carrera, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 2, pp. 216-216
Open Access | Times Cited: 15
Pharmacogenetic Considerations in the Treatment of Alzheimer’s Disease
Ramón Cacabelos, Clara Torrellas, Óscar Teijido, et al.
Pharmacogenomics (2016) Vol. 17, Iss. 9, pp. 1041-1074
Closed Access | Times Cited: 45
Functional AdoMet Isosteres Resistant to Classical AdoMet Degradation Pathways
Tyler D. Huber, Fengbin Wang, Shanteri Singh, et al.
ACS Chemical Biology (2016) Vol. 11, Iss. 9, pp. 2484-2491
Open Access | Times Cited: 44
Pharmacogenomics of Alzheimer’s and Parkinson’s diseases
Ramón Cacabelos
Neuroscience Letters (2018) Vol. 726, pp. 133807-133807
Closed Access | Times Cited: 43
Epigenetic Treatment of Neuropsychiatric Disorders: Autism and Schizophrenia
Walter H. Moos, Eleni Maneta, Carl A. Pinkert, et al.
Drug Development Research (2016) Vol. 77, Iss. 2, pp. 53-72
Closed Access | Times Cited: 37
Exploration of the Therapeutic Potential of the Epigenetic Modulator Decitabine on 6-OHDA-Induced Experimental Models of Parkinson’s Disease
Shobha Kumari, Rajesh Pradhan, Sunil Kumar Dubey, et al.
ACS Chemical Neuroscience (2025)
Closed Access
Pharmacogenetics of Vascular Risk Factors in Alzheimer’s Disease
Ramón Cacabelos, Arun Meyyazhagan, Juan C. Carril, et al.
Journal of Personalized Medicine (2018) Vol. 8, Iss. 1, pp. 3-3
Open Access | Times Cited: 30
Drug Repurposing for Epigenetic Targets Guided by Computational Methods
J. Jesús Naveja, Alfonso Dueñas‐González, José L. Medina‐Franco
Elsevier eBooks (2016), pp. 327-357
Closed Access | Times Cited: 28
Pharmacoepigenetic Processors: Epigenetic Drugs, Drug Resistance, Toxicoepigenetics, and Nutriepigenetics
Ramón Cacabelos, Juan C. Carril, Ana Sanmartín, et al.
Elsevier eBooks (2019), pp. 191-424
Closed Access | Times Cited: 28
The Epigenetic Machinery in the Life Cycle and Pharmacoepigenetics
Ramón Cacabelos, Iván Tellado, Pablo Cacabelos
Elsevier eBooks (2019), pp. 1-100
Closed Access | Times Cited: 23
Page 1 - Next Page

Scroll to top